Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: Joda
4
Nov 15, 2007 07:36AM
4
Nov 15, 2007 10:29AM
2
Nov 15, 2007 04:57PM

Nov 15, 2007 05:02PM

I believe that by reducing the O/S to 80 million, it will give far greater strength to PTSC going forward. Institutions will want to buy once they see the price at over $5 and additional revenue from licensees. They hold for the medium to long term and as such will effectively remove a good percentage of the O/S from the market. This alone will cause the price to increase faster. As the price increases, the value of the shares available for issue(400 million with a 1-for-5)will give far greater leverage than had there been no reverse.

Look at it this way, say the price goes to $5 without a split, there would be at best $500 million in paper for M&A. If the price would go to $5 without a split, it would go higher proportionally than five-fold, for the reaons given above with a split. 400 million x $25, in paper, makes most companies potential targets. I know which I'd prefer.

 

 

 

Be well 

5
Nov 16, 2007 03:14AM
2
Nov 16, 2007 03:54AM
1
Nov 16, 2007 04:33AM
1
Nov 16, 2007 04:38AM
4
Nov 16, 2007 04:42AM

Nov 16, 2007 04:43AM
2
Nov 16, 2007 04:44AM
1
Nov 16, 2007 04:48AM

Nov 16, 2007 04:50AM

Nov 16, 2007 04:50AM

Nov 16, 2007 04:51AM
Share
New Message
Please login to post a reply